TY - JOUR
T1 - Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
AU - Weintraub, Daniel
AU - Dietz, Nicole
AU - Duda, John E.
AU - Wolk, David A.
AU - Doshi, Jimit
AU - Xie, Sharon X.
AU - Davatzikos, Christos
AU - Clark, Christopher M.
AU - Siderowf, Andrew
N1 - Funding Information:
This work was supported by a health research grant [grant number SAP4100027296] awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77, the National Institute of Neurological Disorders and Strokes [NS-053488], and the National Institute of Aging [R01-14971 and P30-AG10124].
PY - 2012/1
Y1 - 2012/1
N2 - Research suggests overlap in brain regions undergoing neurodegeneration in Parkinson's and Alzheimer's disease. To assess the clinical significance of this, we applied a validated Alzheimer's disease-spatial pattern of brain atrophy to patients with Parkinson's disease with a range of cognitive abilities to determine its association with cognitive performance and decline. At baseline, 84 subjects received structural magnetic resonance imaging brain scans and completed the Dementia Rating Scale-2, and new robust and expanded Dementia Rating Scale-2 norms were applied to cognitively classify participants. Fifty-nine non-demented subjects were assessed annually with the Dementia Rating Scale-2 for two additional years. Magnetic resonance imaging scans were quantified using both a region of interest approach and voxel-based morphometry analysis, and a method for quantifying the presence of an Alzheimer's disease spatial pattern of brain atrophy was applied to each scan. In multivariate models, higher Alzheimer's disease pattern of atrophy score was associated with worse global cognitive performance (β=-0.31, P=0.007), including in non-demented patients (β=-0.28, P=0.05). In linear mixed model analyses, higher baseline Alzheimer's disease pattern of atrophy score predicted long-term global cognitive decline in non-demented patients [F(1,110)=9.72, P=0.002], remarkably even in those with normal cognition at baseline [F(1,80)=4.71, P=0.03]. In contrast, in cross-sectional and longitudinal analyses there was no association between region of interest brain volumes and cognitive performance in patients with Parkinson's disease with normal cognition. These findings support involvement of the hippocampus and parietal-temporal cortex with cognitive impairment and long-term decline in Parkinson's disease. In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease.
AB - Research suggests overlap in brain regions undergoing neurodegeneration in Parkinson's and Alzheimer's disease. To assess the clinical significance of this, we applied a validated Alzheimer's disease-spatial pattern of brain atrophy to patients with Parkinson's disease with a range of cognitive abilities to determine its association with cognitive performance and decline. At baseline, 84 subjects received structural magnetic resonance imaging brain scans and completed the Dementia Rating Scale-2, and new robust and expanded Dementia Rating Scale-2 norms were applied to cognitively classify participants. Fifty-nine non-demented subjects were assessed annually with the Dementia Rating Scale-2 for two additional years. Magnetic resonance imaging scans were quantified using both a region of interest approach and voxel-based morphometry analysis, and a method for quantifying the presence of an Alzheimer's disease spatial pattern of brain atrophy was applied to each scan. In multivariate models, higher Alzheimer's disease pattern of atrophy score was associated with worse global cognitive performance (β=-0.31, P=0.007), including in non-demented patients (β=-0.28, P=0.05). In linear mixed model analyses, higher baseline Alzheimer's disease pattern of atrophy score predicted long-term global cognitive decline in non-demented patients [F(1,110)=9.72, P=0.002], remarkably even in those with normal cognition at baseline [F(1,80)=4.71, P=0.03]. In contrast, in cross-sectional and longitudinal analyses there was no association between region of interest brain volumes and cognitive performance in patients with Parkinson's disease with normal cognition. These findings support involvement of the hippocampus and parietal-temporal cortex with cognitive impairment and long-term decline in Parkinson's disease. In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease.
KW - Alzheimer's disease
KW - Parkinson's disease
KW - dementia
KW - mild cognitive impairment
KW - neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=84856704601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856704601&partnerID=8YFLogxK
U2 - 10.1093/brain/awr277
DO - 10.1093/brain/awr277
M3 - Article
C2 - 22108576
AN - SCOPUS:84856704601
SN - 0006-8950
VL - 135
SP - 170
EP - 180
JO - Brain
JF - Brain
IS - 1
ER -